Compounds that modulate intracellular calcium
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07D-417/04
C07D-401/04
C07D-417/14
출원번호
US-0028412
(2014-10-07)
등록번호
US-9611263
(2017-04-04)
국제출원번호
PCT/US2014/059532
(2014-10-07)
국제공개번호
WO2015/054283
(2015-04-16)
발명자
/ 주소
Cao, Jianguo
Wang, Zhijun
Grey, Jonathan
Rogers, Evan
Whitten, Jeffrey P.
출원인 / 주소
CALCIMEDICA, INC.
대리인 / 주소
Wilson, Sonsini, Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
80
초록▼
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
대표청구항▼
1. A compound having the structure of Formula (I): wherein:R1 is L1 is —NHC(═O)—, —C(═O)NH—, or —N(R6)CH2—;R2 is aryl or heteroaryl, wherein aryl or heteroaryl is substituted with at least one R3;R3 is independently selected from halogen, C1-C6alkyl, C1-C6haloalkyl, or C1-C6fluoroalkoxy;R4 is haloge
1. A compound having the structure of Formula (I): wherein:R1 is L1 is —NHC(═O)—, —C(═O)NH—, or —N(R6)CH2—;R2 is aryl or heteroaryl, wherein aryl or heteroaryl is substituted with at least one R3;R3 is independently selected from halogen, C1-C6alkyl, C1-C6haloalkyl, or C1-C6fluoroalkoxy;R4 is halogen;R5 is optionally substituted aryl, or optionally substituted heteroaryl;R6 is H, or C1-C6alkyl;R9 is —CN, —CF3, —CF2H, C1-C6alkyl, or C3-C6cycloalkyl; andn is an integer selected from 0-2; ora pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof. 2. The compound of claim 1 wherein L1 is —NHC(═O)—. 3. The compound of claim 2 wherein R2 is phenyl substituted with at least one R3. 4. The compound of claim 2 wherein R2 is phenyl substituted with at least two R3. 5. The compound of claim 2 wherein R2 is phenyl substituted with at least three R3. 6. The compound of claim 2 wherein R2 is heteroaryl substituted with at least one R3. 7. The compound of claim 6 wherein R2 is pyridyl substituted with at least one R3. 8. The compound of claim 3 wherein each R3 is independently selected from F and CH3. 9. The compound of claim 1 wherein R9 is C3-C6cycloalkyl. 10. The compound of claim 9 wherein R9 is cyclopropyl. 11. The compound of claim 1 wherein R9 is —CF3. 12. The compound of claim 1 wherein R5 is optionally substituted aryl. 13. The compound of claim 12 wherein R5 is optionally substituted phenyl. 14. The compound of claim 1 wherein R5 is optionally substituted heteroaryl. 15. The compound of claim 14 wherein R5 is optionally substituted thiazolyl. 16. The compound of claim 14 wherein R5 is optionally substituted oxazolyl. 17. The compound of claim 1 wherein n is 0. 18. The compound of claim 1 wherein n is 1. 19. The compound of claim 18 wherein R4 is F. 20. A compound having the structure of Formula (II): wherein:R1 is L1 is —NHC(═O)—, —C(═O)NH—, or —N(R6)CH2—;Y is CR8, or N;R2 is aryl or heteroaryl, wherein aryl or heteroaryl is substituted with at least one R3;R3 is independently selected from halogen, C1-C6alkyl, C1-C6haloalkyl, or C1-C6fluoroalkoxy;R4 is halogen;R5 is optionally substituted aryl, or optionally substituted heteroaryl;R6 is H, or C1-C6alkyl;R8 is H, or halogen;R9 is —CN, —CF3, —CF2H, C1-C6alkyl, or C3-C6cycloalkyl; andn is an integer selected from 0-2; ora pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof. 21. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient, carrier or binder, and a compound of claim 1 or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (80)
Belley Michel,CAX ; Gauthier Jacques Yves,CAX ; Grimm Erich,CAX ; LeBlanc Yves,CAX ; Li Chun-Sing,CAX ; Therien Michel,CAX ; Black Cameron,CAX ; Prasit Petpiboon,CAX ; Lau Cheuk-Kun,CAX ; Roy Patrick, (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors.
Black Cameron (Pointe Claire CAX) Mancini Joseph A. (St. Leonard CAX) Lau Cheuk K. (Ile Bizard CAX) Prasit Petpiboon (Kirkland CAX) Vickers Philip J. (Pierrefonds CAX 4), 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents.
Norman Bryan H. (St. Charles MO) Lee Len F. (St. Charles MO) Masferrer Jaime L. (Ballwin MO) Talley John J. (St. Louis MO), 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents.
Black Cameron (Pointe Claire CAX) Leger Serge (Dollard des Ormeaux CAX) Prasit Petpiboon (Kirkland CAX) Wang Zhaoyin (Pierrefonds CAX) Hamel Pierre (Laval CAX) Han Yongxin (Kirkland CAX) Hughes Grego, 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors.
Black W. Cameron (Pointe-Claire CAX) Li Chun-Sing (Dollard Des Ormeaux CAX) Guay Daniel (Notre Dame de L\lle Perrot CAX) Prasit Petpiboon (Kirkland CAX) Roy Patrick (Dollard Des Ormeaux CAX), Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Kris P. Antonsen ; Rajiv Nayar ; Wei Wang ; Margaret Caudle ; Michael A. Shearer ; Neville M. Concessio, Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations.
Dansereau Richard J. (Sherburne NY) Mosher Russell Y. (Norwich NY) Axelrod Douglas W. (Norwich NY) Sietsema William K. (Norwich NY), Dosage forms of risedronate.
Chandrasekaran Santosh Kumar (Palo Alto CA) Urquhart John (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Method and therapeutic system for providing chemotherapy transdermally.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Kelm Gary Robert (Cincinnati OH) Manring Gary Lee (Hamilton OH), Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery.
Talley John J ; Malecha James W ; Bertenshaw Stephen ; Graneto Matthew J ; Carter Jeffery ; Li Jinglin ; Nagarajan Srinivasan ; Brown David L ; Rogier ; Jr. Donald J ; Penning Thomas D ; Khanna Ish K, Prodrugs of benzenesulfonamide-containing COX-2 inhibitors.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Talley John J. (8772 Pine Ave. Brentwood MO 63144) Brown David L. (15504 Twingate Chesterfield MO 63017) Nagarajan Srinivasan (16209 Forest Meadows Dr. Chesterfield MO 63017) Carter Jeffery S. (15321, Substituted isoxazoles for the treatment of inflammation.
Talley John J. (St. Louis MO) Penning Thomas D. (Elmhurst IL) Collins Paul W. (Deerfield IL) Rogier ; Jr. Donald J. (St. Louis MO) Malecha James W. (Libertyville IL) Miyashiro Julie M. (Chicago IL) B, Substituted pyrazolyl benzenesulfonamides.
Reitz David B. (Chesterfield MO) Manning Robert E. (St. Louis MO) Huang Horng-Chi (Chesterfield MO) Li Jinglin (Chesterfield MO), Substituted spiro compounds for the treatment of inflammation.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Davis Roosevelt (27 Lullwater Estate Rd. Atlanta GA 30307) Primo-Davis Susan A. (27 Lullwater Estate Rd. Atlanta GA 30307), Transdermal therapeutic formulation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.